Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA Knockdown

CRISPR-based genome/epigenome editing and RNA-targeted therapeutics offer unprecedented precision for correcting disease-causing mutations, yet clinical translation remains constrained by two unresolved bottlenecks: suboptimal guide RNA (gRNA) design limiting editing efficiency and specificity, and the absence of safe, tissue-selective delivery platforms. While machine learning (ML)-driven gRNA design and peptide-mediated delivery have each advanced substantially in isolation, to our knowledge, no existing framework jointly optimizes predictive guide-design models and delivery-vector design within a single pipeline a disconnect that likely underlies persistent efficacy–safety trade-offs in clinical translation. This review addresses that gap by critically synthesizing ML-driven guide design and peptide-engineered delivery within a single mechanistic and computational framework. We first outline the structural basis of peptide-derived vectors, emphasizing how charge, hydrophobicity, secondary structure, and receptor-targeting functionalization govern organ- and cell-type specificity. We then critically appraise ML methods for predicting on-target activity, off-target propensity, and specificity across CRISPR platforms, alongside computational approaches for non-coding RNA target identification, focusing on training-data limitations, feature representation, and cross-platform generalizability that constrain predictive reliability. We synthesize design principles for tissue-specific delivery, including nanocarrier integration, and highlight preclinical cases where ML-guided peptide engineering enabled targeted delivery of mRNA, antisense oligonucleotides, and CRISPR ribonucleoproteins. Finally, we assess persistent barriers data sparsity, limited model transferability, off-target genotoxicity, immunogenicity, and delivery constraints and propose emerging directions: multi-omics integration, AI-enabled de novo peptide design, and translational frameworks. This review establishes a convergent paradigm in which joint ML-guided optimization of guide and delivery design enhances the specificity, efficiency, and safety of next-generation precision genetic medicines.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210322
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA Knockdown

Shukur Wasman Smail, Abbas Burhan Salihi, Snur Rasool Abdullah
International Journal of Molecular Sciences
CRISPR and Genetic Engineering
article

Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA Knockdown

Shukur Wasman Smail, Abbas Burhan Salihi, Snur Rasool Abdullah
article en

Abstract

CRISPR-based genome/epigenome editing and RNA-targeted therapeutics offer unprecedented precision for correcting disease-causing mutations, yet clinical translation remains constrained by two unresolved bottlenecks: suboptimal guide RNA (gRNA) design limiting editing efficiency and specificity, and the absence of safe, tissue-selective delivery platforms. While machine learning (ML)-driven gRNA design and peptide-mediated delivery have each advanced substantially in isolation, to our knowledge, no existing framework jointly optimizes predictive guide-design models and delivery-vector design within a single pipeline a disconnect that likely underlies persistent efficacy–safety trade-offs in clinical translation. This review addresses that gap by critically synthesizing ML-driven guide design and peptide-engineered delivery within a single mechanistic and computational framework. We first outline the structural basis of peptide-derived vectors, emphasizing how charge, hydrophobicity, secondary structure, and receptor-targeting functionalization govern organ- and cell-type specificity. We then critically appraise ML methods for predicting on-target activity, off-target propensity, and specificity across CRISPR platforms, alongside computational approaches for non-coding RNA target identification, focusing on training-data limitations, feature representation, and cross-platform generalizability that constrain predictive reliability. We synthesize design principles for tissue-specific delivery, including nanocarrier integration, and highlight preclinical cases where ML-guided peptide engineering enabled targeted delivery of mRNA, antisense oligonucleotides, and CRISPR ribonucleoproteins. Finally, we assess persistent barriers data sparsity, limited model transferability, off-target genotoxicity, immunogenicity, and delivery constraints and propose emerging directions: multi-omics integration, AI-enabled de novo peptide design, and translational frameworks. This review establishes a convergent paradigm in which joint ML-guided optimization of guide and delivery design enhances the specificity, efficiency, and safety of next-generation precision genetic medicines.

International Journal of Molecular SciencesVol. 27(22)
Uppsala University (SE), Uppsala University Hospital (SE), Lebanese French University (IQ), Salahaddin University-Erbil (IQ)
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon